American Academy of Neurology

bluebird bio Inc (NASDAQ: BLUE) presented interim data for the Phase II/III trials of its lead gene therapy LentiD in CCALD, a rare neurodegenerative disorder, at the American Academy of Neurology (AAN) meeting. Goldman Sachs’ Salveen Richter maintained a Neutral rating on the company, with...

Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting. Bio Blast Pharma is a clinical-stage...

In a report released Tuesday, Jefferies reiterated a Buy rating and a $410 price target (set in July) for Biogen Idec Inc (NASDAQ: BIIB). The analysts say that they feel “encouraged by the incremental color on BIIB037, suggesting the results may be more robust than we [the analysts]...